Retractable Technologies, Inc. (NYSE AMEX: RVP), a leading maker of safety medical devices, reported an operating loss of $1.1 million for the nine months ended September 30, 2011, compared to an operating loss of $4.2 million for the same period last year.
Comparison of Three Months Ended September 30, 2011 and September 30, 2010
Domestic sales accounted for 96.2% and 80.1% of the revenues for the three months ended September 30, 2011 and 2010, respectively. Domestic revenues decreased 18.8% principally due to lower sales volumes and lower average sales prices. Domestic unit sales decreased 7.8%. Domestic unit sales were 94.7% of total unit sales for the three months ended September 30, 2011. International unit sales and revenues decreased 89.5% and 87.1%, respectively. Overall, unit sales decreased 34.7%.
Gross profit decreased 34.8% primarily due to lower revenues. The average cost of manufactured product sold per unit increased by 6.1%. Profit margins can fluctuate depending upon, among other things, the cost of manufactured product and the capitalized cost of product recorded in inventory, as well as product sales mix. Royalty expense decreased 29.5% due to lower gross sales.Operating expenses decreased 18.4% or $769 thousand. The decrease in General and administrative expense was the most significant. The decrease of $420 thousand in General and administrative expense was due mainly to bonuses paid in 2010. Sales and marketing expense decreased 17.7% due principally to bonuses paid in 2010 and lower fee expenses. Research and development costs decreased 46.4% due to lower validation and sampling costs. Our operating loss was $26 thousand compared to an operating income for the same period last year of $1.0 million due primarily to lower revenues, mitigated by a reduction in operating expenses. Litigation settlements, net reflects cash proceeds of $2.0 million from Hospira less royalty expense of $100,000 for the three months ended September 30, 2011. Litigation settlements, net for the three months ended September 30, 2010 reflects our settlement with Abbott and Hospira, including a payment of $6.0 million, a waiver of an invoice due to us of $144,000, and a $1.4 million marketing fee payable to Abbott.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV